45 patents
Utility
Highly Sialylated Multimeric Binding Molecules
9 Mar 23
This disclosure provides a monoclonal population of highly sialylated multimeric binding molecules where the population includes IgM antibodies, IgM-like antibodies, or other IgM-derived binding molecules, where the population of binding molecules has a higher level of sialic acid content than is found in normal serum IgM.
Bruce KEYT, Ramesh BALIGA, Sachi AHMED, Kevin CARLIN, Paul HINTON, Mark SMITH, Avneesh SAINI, Huyen TRAN, Marvin PETERSON
Filed: 5 Jan 21
Utility
Multimeric Coronavirus Binding Molecules and Uses Thereof
23 Feb 23
This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2.
Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
Filed: 27 Jul 21
Utility
Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules
14 Feb 23
This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
Beatrice Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga
Filed: 28 Apr 20
Utility
Modified J-chain
17 Jan 23
The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.
Bruce Keyt, Leonard George Presta, Fen Zhang, Ramesh Baliga
Filed: 19 Sep 18
Utility
Binding molecules with modified J-chain
3 Jan 23
The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.
Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
Filed: 16 Jan 20
Utility
Multi-valent hepatitis B virus antigen binding molecules and uses thereof
27 Dec 22
This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain.
Stephen F. Carroll, Ramesh Baliga, Dean Ng, Bruce Keyt
Filed: 19 Feb 20
Utility
Multimeric Coronavirus Binding Molecules and Uses Thereof
22 Dec 22
This disclosure provides multimeric binding molecules that bind to a human coronavirus, e.g., MERS-CoV, SARS-CoV or SARS-CoV-2.
Paul R. Hinton, Bruce Alan Keyt, Dean Ng, Kathy Miller, Deepal Pandya, Stephen F. Carroll
Filed: 14 Jul 22
Utility
Multimeric Antibodies with Enhanced Selectivity for Cells with High Target Density
24 Nov 22
This disclosure provides a multimeric binding molecule, e.g., an IgM, IgM-like, IgA, or IgA-like binding molecule, e.g., an antibody with enhanced selectivity for cells expressing a target antigen at high density, e.g., tumor cells.
Ramesh BALIGA, Paul HINTON, Bruce KEYT
Filed: 18 Sep 20
Utility
Modified Human Igm Constant Regions for Modulation of Complement-dependent Cytolysis Effector Function
27 Oct 22
The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the Cμ3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.
Ramesh BALIGA, Dean NG
Filed: 10 Jun 22
Utility
Igm Glycovariants
29 Sep 22
This disclosure provides an isolated IgM-derived binding molecule, e.g., an IgM antibody, IgM-like antibody, or other IgM-derived binding molecule, including at least one variant IgM-derived heavy chain, where the at least one variant IgM-derived heavy chain includes a variant IgM heavy chain constant region associated with a binding domain that specifically binds to a target, where at least one asparagine (N)-linked glycosylation motif of the variant IgM heavy chain constant region is mutated to prevent glycosylation at that motif, and/or at least one N-linked glycosylation motif is introduced into the variant IgM heavy chain.
Bruce KEYT, Dean NG, Ramesh BALIGA
Filed: 21 Aug 20
Utility
Multimeric Bispecific ANTI-CD123 Binding Molecules and Uses Thereof
15 Sep 22
This disclosure provides multivalent, bispecific, anti-CD123 binding molecule comprising a modified J-chain that specifically binds to an immune effector cell.
Manal AMOURY, Angus SINCLAIR, Bruce KEYT
Filed: 14 Aug 20
Utility
Multimeric SARS-COV-2 Binding Molecules and Uses Thereof
25 Aug 22
This disclosure provides multimeric binding molecules that bind to SARS-CoV-2.
Zhiqiang KU, Xuping XIE, Paul HINTON, Ningyan ZHANG, Bruce KEYT, Dean NG, Stephen CARROLL, Pei-Yong SHI, Zhiqiang AN
Filed: 15 Feb 22
Utility
Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
2 Aug 22
The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the Cμ3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.
Ramesh Baliga, Dean Ng
Filed: 6 Apr 18
Utility
Novel Diaroyl Carbazole Compound and Use Thereof As Sensitising Agent
16 Jun 22
Provided in the present invention is a novel diaroyl carbazole compound, used together with a carbazolyl oxime ester photo initiator to show a significant synergistic initiation effect in a photoresist composition; the best sensitising effect is shown when the molar ratio of the diaroyl carbazole compound and the carbazolyl oxime ester photoinitiator is 0.1-1.4
Wenchao Zhao, Jiaqi Li, Zhongli Ma, Chenlong Wang, Yonglin Wang
Filed: 17 Mar 20
Utility
Multimeric Gitr Binding Molecules and Uses Thereof
9 Jun 22
This disclosure provides dimeric, pentameric, and hexameric GITR agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
Beatrice Tien-Yi WANG, Bruce Alan KEYT, Ramesh BALIGA
Filed: 24 Feb 22
Utility
Photoinitiator Composition Containing Acylcarbazole Derivative and Carbazolyl Oxime Ester, and Use Thereof In Photocurable Composition
9 Jun 22
Provided is a photoinitiator composition containing an acylcarbazole derivative and a carbazolyl oxime ester.
Wenchao Zhao, Chenlong Wang, Jiaqi Li, Yonglin Wang
Filed: 17 Mar 20
Utility
Multimeric OX40 Binding Molecules and Uses Thereof
2 Jun 22
This disclosure provides dimeric, pentameric, and hexameric OX40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
Beatrice Tien-Yi WANG, Dalya Rivka ROSNER, Ramesh BALIGA, Bruce KEYT
Filed: 17 Feb 22
Utility
Multimeric CD137/4-1BB Binding Molecules and Uses Thereof
16 Dec 21
This disclosure provides dimeric, pentameric, and hexameric CD137/4-1BB agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
Bruce KEYT, Ramesh BALIGA, Beatrice Tien-Yi WANG
Filed: 17 Aug 21
Utility
MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
9 Dec 21
This disclosure provides IgM- and IgA-derived binding molecules comprising binding polypeptides, e.g., receptor ectodomains, ligands, or receptor-binding fragments thereof, and the like, fused to multimerizing IgM or IgA constant regions.
Ramesh BALIGA, Paul HINTON, Dean NG, Bruce KEYT
Filed: 23 Oct 19
Utility
Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
7 Dec 21
This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain.
Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
Filed: 7 Jan 20